Inventiva unveils its 2024 financial results and strategic projects

Inventiva, a biopharmaceutical company with operations listed in Paris and New York, announced revenue of €9.2 million for the fiscal year 2024 and cash of €96.6 million at the end of the year. It raised €116 million through structured financing of up to €348 million. 2024 saw the completion of patient recruitment for the Phase 3 NATiV3 study of lanifibranor in MASH, with completion expected in 2025. A reorganization project, including the cessation of preclinical research and a 50% reduction in staff, has been proposed to refocus its efforts on the development of lanifibranor.

Research and development expenses decreased 17% to €90.9 million, primarily due to a temporary suspension of NATiV3 study enrollment following unforeseen medical events. The company also incurred non-cash financial expenses of €73.4 million related to the recognition of derivative instruments. Inventiva expects to fund its operations through the third quarter of 2026, if the next target financing rounds are met.